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Injurious Commissions also include severely restrictive – and  
inefficient – trade barriers that curb exports from poorer countries. 
Amartya Sen, Identity and Violence1 
 
I. Introduction 
A 2005 publication of UNAIDS, AIDS in Africa: Three Scenarios to 2025, contains several 
moving stories about HIV/AIDS in Africa, describing how the AIDS epidemic in Africa could 
evolve over the next 20 years.2 The scenarios set out to answer one central question: over the 
next 20 years, what factors will drive Africa’s and the world’s responses to the AIDS epidemic, 
and what kind of future will there be for the next generation? Amongst the various aspects of 
the problem, access to and uptake of AIDS treatment is discussed and highlighted throughout 
the document. The publication highlights how crucial Indian pharmaceutical exports are for 
the treatment of the HIV/AIDS epidemic in Africa.  
African nations and many other developing countries require access to essential medicines to 
address public health concerns. The creation of a safe, secure and reliable access to an essential 
medicines regime depends upon a number of factors ranging from mobilisation of resources to 
administration of drugs to those who badly need them in extreme poverty situations. Factors 
such as resources prioritisation, adequate procurement policies, supporting infrastructure and 
trained personnel are definitely very crucial for any successful essential drugs program. 
However, the most critical factor is the very availability of the medicines which could then be 
provided to those who need them. The most crucial and the daunting barrier increasingly faced 
in this regard is the accessibility to safe and affordable medicines to keep up the life expectancy 
trajectory of millions of poor patients around the world.  
According to available research, Indian generic pharmaceutical companies provide a major 
portion of pharmaceutical products which are procured by various international and regional 
organisations for their treatment projects related to HIV/AIDS, malaria and tuberculosis.3 The 
 
1 Amartya Sen, Identity and Violence (New York: W.W. Norton & Company, 2006) 140.  
2 United Nations Programme on HIV/AIDS (UNAIDS), AIDS in Africa: Three scenarios to 2025, 2005 at 
http://www.unaids.org/unaids_resources/images/AIDSScenarios/AIDS-scenarios-2025_report_en.pdf.  
3 Padmashree Hehi Sampath, ‘Economic Aspects of Access to Medicines after 2005: Product Patent Protection and 
Emerging Firm Strategies in the Indian Pharmaceutical Industry’ (Accessed on July 12, 2009) Institute of New 
Technologies, United Nations University at http://www.who.int/intellectualproperty/studies/
PadmashreeSampathFinal.pdf. 
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following table shows the list of top ten suppliers of Antiretroviral (ARV) drugs under the 
Global Fund’s procurement program.  
Table 1.1: Top Ten Suppliers of ARVs under Global Fund in Terms of Consignments (June 2003-Jan 2006) 
Manufacturer Total No. of Consignments 
Cipla Ltd. 342 
Aspen Pharmacare 221 
Bristol Myers Squibb 158 
GlaxoSmithKline Ltd. 144 
Abbott Laboratories 88 
Merck 73 
Ranbaxy Laboratories 45 
Hetro Drugs Ltd. 35 
Roche 32 
Boehringer Ingelheim 25 
Source: Global Fund as cited by Biswajit Dhar4 
 
Table 4.1 shows that although four Indian firms are among the top ten suppliers by volume, in 
terms of value only two appeared in the top ten, because of their lower prices.5 Another source 
cites the data of Global Fund’s suppliers in terms of brand names and generics. It shows that in 
2004, brand name, patented, manufacturers supplied 40.7% of total procurements by volume 
but their share in expenditure terms was around 53%, whereas, generic manufacturers supplied 
almost 59.3% of the volume of total drugs with only a 47% share of expenditures.6 Other 
international humanitarian agencies like UNICEF and the Clinton Foundation rely heavily on 
importing affordable drugs from India. Indeed 84% of the ARVs that Médecins Sans Frontières 
prescribes to its patients worldwide come from Indian generic companies.7 
There has been much debate as to whether India will be able to continue to be such a 
dominant supplier of generic medicines, in an era where it must be compliant with the TRIPS 
 
4 Biswajit Dhar and K.K. Gopakumar, ‘Post-2005 TRIPS scenario in patent protection in the pharmaceutical 
sector: The case of generic pharmaceutical industry in India’ (2006), UNCTAD, IDRC and ICTSD, 57 at 
http://www.measwatch.org/autopage/file/MonMarch2009-14-25-16-IndianINDUSTRY.pdf. 
5 Ibid. 56.  
6 Kenneth C. Shalden, ‘The Political Economy of AIDS Treatment: Intellectual Property and the Transformation 
of Generic Supply’ (2007) 51 International Studies Quarterly 559-581, 564. 
7 Gustavo Capdevila, ‘Indian court rejects Novartis’ drug patent suit’ Asia Times online, 8 August 2007, 
http://www.atimes.com/atimes/South_Asia/IH08Df01.html.  
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Agreement 1994. Several studies consider whether compulsory licensing will be an effective tool 
to maintain the current level of supplies from Indian generic manufacturers.8 We can see four 
different strategies bearing on the relevancy and usefulness of compulsory licensing as a means 
of providing access to medicines. First of all, multinational brand-name pharmaceutical 
companies represented by Pharmaceutical Research and Manufacturers of America (PhRMA) 
have favoured a narrow and limited scope for compulsory licensing mechanisms. Accordingly, 
this industry is largely comfortable with the Waiver Decision 2003 and the way in which 
limitations and restrictions are imposed on the issuance of compulsory licences. Second, a 
number of academics and commentators contend that the compulsory licensing arrangements 
under the Waiver Decision 2003 will have a positive impact on pharmaceutical export 
mechanisms. Scholars like Frederick Abbott and Jerome H. Reichman belong to this group 
when they argue that export mechanisms can be boosted through a well-designed 
implementation strategy.9 Third, civil society groups such as Médecins Sans Frontières (MSF) and 
Knowledge Ecology International (KEI) hold critical positions about the negative implications 
of the Waiver Decision 2003 on export mechanisms. They argue that the complicated and 
cumbersome procedure envisaged under the Waiver Decision 2003 will inevitably limit the 
ability of export markets to meet the demands of poor and developing countries. Finally, there 
is a group of commentators who contend that the Waiver Decision 2003 has a symbolic 
significance, even though its practical, tangible impact is negligible. Employing the themes of 
rule complexity and regulatory ritualism, Professor Peter Drahos has highlighted the limitations 
of the Waiver Decision 2003 to show the futility of outcome.10 
This chapter contends that the compulsory licensing mechanism for exports under the Waiver 
Decision 2003 lacks efficacy. It argues that the Indian compulsory licensing regime fails to 
facilitate affordable drug supply to other developing countries, because of the rigidity and 
complexity of treaty rules; economic considerations; technological constraints and capacity; and 
a fickle lack of political commitment. The main hypothesis extended is that without a viable, 
affordable and continuous generic supply from India, the success of Doha Declaration 2001 
 
8 See for example: Biswajit Dhar and K.K. Gopakumar, ‘Post-2005 TRIPS scenario in patent protection in the 
pharmaceutical sector: The case of generic pharmaceutical industry in India’ (2006), UNCTAD, IDRC and 
ICTSD, 56; Alka Chadha, ‘Product Cycles, innovation and exports: A Study of Indian pharmaceuticals’ (2005), 
Department of Economics, National University of Singapore Working Paper No. 0511 at 
http://www.fas.nus.edu.sg/ecs/pub/wp/wp0511.pdf. Also see: Padmashree Gehl Sampath, ‘Economic Aspects of 
Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian 
Pharmaceutical Industry’ Institute of New Technologies, United Nations University at 
http://www.who.int/intellectualproperty/studies/PadmashreeSampathFinal.pdf.  
9 Frederick M. Abbott and Jerome H. Reichman, ‘The Doha Round Public Health Legacy: Strategies for the 
Production and Diffusion of Patented Medicines Under the Amended TRIPS Provisions’ (2007) 10(4) Journal of 
International Economic Law 921-987, 941. 
10 Peter Drahos, ‘Four Lessons for Developing Countries from the Trade Negotiations over Access to Medicines’ 
(2007) 28(11) Liverpool Law Review 39 at http://www.anu.edu.au/fellows/pdrahos/pdfs/
2007fourlessonsfordevcountries.pdf.  
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would be substantially compromised. Part II of this chapter deals with the key provisions in the 
TRIPS Agreement 1994 dealing with the exports of pharmaceutical drugs. Part III considers the 
Doha Declaration 2001 and the subsequent Waiver Decision 2003. Part IV considers the various 
species of compulsory licensing under Indian patent law. Part V considers the first Indian 
compulsory licensing instance under the new law and the Natco’s application for the grant of 
compulsory licences of erlotinib and sutent.  
II. The TRIPS Agreement 1994 and Pharmaceutical Exports  
Before the adoption of the TRIPS Agreement 1994, developing countries were largely free to 
determine the scope, term and availability of patent protection as a part of their overall 
industrial and public health policy objectives. Although many developing countries were 
members of the Paris Convention for the Protection of Industrial Property of 1883 (Paris Convention 
1883), they retained the flexibility to legislate on domestic pharmaceutical production and 
access to essential medicines. In terms of substantive rule-making, patentable subject matter, 
local usage and enforcement measures, the Paris Convention 1883 leaves considerable space for 
Member States to devise and implement their own patent systems. Indeed, it even allows 
Member States to deny protection for certain subject matters such as pharmaceutical products.  
However, under the TRIPS Agreement 1994, all Member States are now required to comply with 
the minimum standards set out in the treaty. The obligations of the TRIPS Agreement 1994 
include the extension of patent protection to all qualifying inventions without the 
discrimination of any field of technology and origin of subject matter.11 Thus the developing 
countries were obligated to extend patent protection to pharmaceutical products pursuant to 
the requirements of the TRIPS Agreement 1994. Since the expiry of the limited transition period 
in 2005, the situation has radically changed in developing countries and they have introduced 
new laws and governing regulations dealing with the patentability of medicines and related 
components. In 1994, India decided to take advantage of the transitional period allowed under 
the TRIPS Agreement 1994 for developing countries, which ultimately ended in 2005.  
The TRIPS Agreement 1994 recognises the right of member countries to issue compulsory 
licences subject to procedural requirements laid down in Article 31. However, the option of 
invoking Article 31 flexibilities to meet public health objectives had no real meaning for many 
developing and least developing countries because they lacked any local pharmaceutical 
manufacturing capabilities. The problem is directly linked with the language of Article 31(f) of 
the TRIPS Agreement 1994 which, after initially allowing the grant of a compulsory licence, 
restricts the operation of this option by stating: 
 
11 Article 27.1 of the TRIPS Agreement 1994. 
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(f) any such use shall be authorized predominantly for the supply of the domestic 
market of the Member authorizing such use; 
However, in practice, many developing and least developing countries lacked sufficient 
manufacturing capacity for the production of highly advanced and technologically sophisticated 
medicines to address public health epidemics. They did not have even a possibility of getting 
cheaper medicines from India, China or Brazil under a compulsory licence because any such 
production in these countries was supposed to be predominantly for the supply of the local 
market and only a fraction of total produce was allowed to be exported to the countries which 
mainly needed these drugs.  
The WTO Ministerial Conference adopted the Doha Declaration 200112 in November 2001. 
This was the product of an extensive lobbying effort of international humanitarian 
organisations, NGOs and the governments of developing and least developing countries. The 
Doha Declaration 2001 reaffirmed the flexibilities built into the TRIPS Agreement 1994, including 
the right of Member States to issue compulsory licences on public interest grounds.13 The 
Declaration then specifically addressed the problem of Member States lacking the capacity to 
manufacture cheaper generic substitutes and which are otherwise not capable of exploiting the 
flexibilities under the existing Article 3(f) requirement. Paragraph 6 of the Doha Declaration 
2001 mandated the relevant WTO body to work out a suitable solution, keeping in view the 
limitations of such countries with an aim to ensure access to essential medicines.14  
After almost two years of extensive discussions at WTO a solution, initially embodied in the 
form of a Waiver, was reached on 30 August 2003 (Waiver Decision 2003).15 In the light of 
various proposals and discussions, it was decided that this Waiver Decision 2003 would be 
rendered as permanent in the form of an amendment to the TRIPS Agreement 1994 as Article 
31bis.16 The ratification of the proposed amendment is still pending while Member States 
consider their options. Meanwhile the waiver reached on 30 August 2003 is effective and would 
continue to operate. The Waiver Decision 2003 and the Protocol amending the TRIPS Agreement 
1994 are summarised in the following section along with a brief analysis of some provisions.  
 
12 Doha Declaration on the TRIPS Agreement and Public Health, WTO Doc WT/MIN(01)/DEC/2 (14 November 
2001) at http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm.  
13 Ibid. Paragraph 5(b).  
14 bid. Paragraph 6. 
15 Implementation of Paragraph 6 of the Doha Declaration on TRIPS Agreement and Public Health, WTO Doc WT/L/540 
(30 August 2003) (Decision of the General Council of 30 August 2003) at 
http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm.  
16 WTO General Council Decision of 6 December 2005 Amendment of the TRIPS Agreement, WT/L/641, (8 Dec. 2005) 
(Protocol Amending the TRIPS Agreement’ with Annex setting out Article 31bis) at 
http://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm.  
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III. The Waiver Decision and Proposed Article 31bis 
In 2001, paragraph 6 of the Doha Declaration 2001 recognised that the countries with limited or 
virtually no manufacturing capacity in the pharmaceutical sector had difficulties in invoking the 
compulsory licensing mechanism set out in Article 31 of the TRIPS Agreement 1994. 
Subsequently based upon the mandate of the Doha Declaration 2001, the WTO General 
Council’s Waiver Decision 2003 paved the way to allow countries with sufficient manufacturing 
capacity to make and export pharmaceutical products to countries which require such 
medicines for public health needs. This objective is achieved through a mechanism whereby 
restriction of Article 31(f) is waived for the exporting countries (by relaxing the requirement of 
manufacturing predominantly to the supply of domestic market), and restriction of Article 
31(h)17 is waived for importing countries. Proposed Article 31bis essentially reflects the terms of 
the Waiver Decision 2003 by establishing the waiver of certain obligations of the TRIPS Agreement 
1994 as mentioned earlier.  
A. Scope and Coverage of Diseases 
Paragraph 1 of the Waiver Decision 2003 defines ‘pharmaceutical product’ broadly without 
limiting application of the solution to certain specific diseases. It reads: 
(a) “pharmaceutical product” means any patented product, or product manufactured 
through a patented process, of the pharmaceutical sector needed to address the public 
health problems as recognized in paragraph 1 of the Declaration. It is understood that 
active ingredients necessary for its manufacture and diagnostic kits needed for its use 
would be included.18 
The definition is sufficiently broad as active pharmaceutical ingredients (APIs) and diagnostic 
kits are expressly covered. The definition is also sufficiently broad to cover vaccines because 
vaccines are ‘products of the pharmaceutical sector’. 
The negotiations prior to the adoption of Waiver Decision 2003 were quite extensive with regard 
to the scope and coverage of diseases to be covered under the proposed mechanism. The 
United States proposed to restrict the candidate list of diseases to HIV-AIDS, malaria, 
tuberculosis and a relatively small group of infectious diseases. The US proposal also sought to 
limit the countries that would benefit from the solution and considered it to be the Ministers’ 
 
17 Remuneration requirement is explicitly waived. This aspect is discussed further hereafter.  
18 Implementation of Paragraph 6 of the Doha Declaration on TRIPS Agreement and Public Health, WTO Doc WT/L/540 
(30 August 2003) (Decision of the General Council of 30 August 2003) Paragraph 1 at 
http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm.  
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intention at Doha.19 At some later stage of negotiations, the EC had demonstrated a relatively 
more flexible approach and suggested that the solution be confined to grave public health 
problems and a potential role of WHO was also mentioned to identify such grave situations.20 
On 28 January 2003, India together with several developing countries submitted that they 
would not accept the USA and EC proposals as they would narrow down the scope of 
paragraph 1 of the Doha Declaration.21  
India’s position prevailed. Paragraph 1 of the Doha Declaration 2001 does not mention any 
limitation on the application of the Declaration to certain specific diseases or medicines and 
the position of developing countries was finally reflected in the Waiver Decision 2003. The 
proposed Article 31bis mirrors this stance.  
B. Notification Requirement and Eligible Countries 
Both the Waiver Decision 2003 and the proposed Article 31bis contemplate two important 
notification requirements. The first is a general notification of intent which is required from all 
member countries that use the system, other than least developing countries.22 The group of 
members belonging to least developing countries are thus free to invoke the mechanism 
without any notification of intent. Both the instruments also provide that any Member State 
may notify the TRIPS Council that it does not intend to use the system as an importing country 
or that it only intends to use it in a limited way. Almost all OECD countries have practically 
opted out by notifying their intention not to use the system or to use it in a limited way.23 A 
number of Member States (Hong Kong, China, Israel, Kuwait, Macao Chian, Mexico, Qatar, 
Singapore, Chinese Taipei, Turkey and the United Arab Emirates) notified their intention to 
use the system only in cases of national emergency or other circumstances of extreme urgency.24 
By analogy, one can construe that other non-notifying Member States may then use the system 
liberally in situations other than national emergency or circumstances of extreme urgency.  
 
19 Cecilia Oh, ‘Developing countries criticise attempts to limit scope of diseases in Paragraph 6 negotiations’, Update on 5 
Feb 2003 informal meeting of TRIPS Council and Background to the Negotiations on Para 6, Page 4. at 
http://www.twnside.org.sg/title/TRIPS-Feb5.doc.  
20 Ibid. 
21 Ibid. 3 
22 Paragraph 1(b), WTO General Council Decision of 6 December 2005 Amendment of the TRIPS Agreement, WT/L/641, 
(8 Dec. 2005) (Protocol Amending the TRIPS Agreement’ with Annex setting out Article 31bis) at 
http://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm. 
23 Ibid. Footnote 3 to Paragraph 1(b).  
24 Duncan Matthews, ‘WTO Decision on Implementation of Paragraph 6 of the Doha Declaration on the TRIPS 
Agreement and Public Health: A Solution to the Access to Essential Medicines Problem?’ (2004) 7(1) Journal of 
International Economic Law 73-107, 95. 
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On 19 July 2007, Rwanda became the first WTO Member State which notified its intention to 
use the system to import some 260,000 packs of TriAvir, a fixed-dose combination product of 
Zidovudine, Lamivudine and Nevirapine, from a Canadian pharmaceutical firm Apotex, Inc.25 
It is pertinent to note that Rwanda had no obligation to notify as such being a designated least 
developing country and it was eligible to use the system without following any procedural 
formalities. However, a notification requirement is imposed upon the potential exporting 
WTO Member States pursuant to paragraph 2(c) of the Waiver Decision 2003. In response to the 
request of Rwanda, the Canadian Government notified the TRIPS Council of the terms of the 
export licence it had issued in this regard.26 Some commentators have criticised the elaborate 
and lengthy procedural notification procedure in the Canadian regime.  
C. Determination of Manufacturing Capacity 
According to Article 31bis least developing countries are automatically eligible to import 
medicines under the system envisaged in this regard. In addition to this, any country making a 
determination that it has insufficient or no manufacturing capacity of a particular pharmaceutical 
product, can also become an eligible importing state.27 This Article further provides that the 
determination of manufacturing capacity in this regard by the importing country excludes the 
production facilities which are owned or controlled by the patent holders. It states: 
Where the Member has some manufacturing capacity in this sector, it has examined this 
capacity and found that, excluding any capacity owned or controlled by the patent 
owner, it is currently insufficient for the purposes of meeting its needs. When it is 
established that such capacity has become sufficient to meet the Member’s needs, the 
system shall no longer apply.28 
The language of the Article 31bis about the definition of pharmaceutical product and 
determination of manufacturing capacity would be helpful for a developing country that wants 
to use this system merely to import pharmaceutical products to manufacture medicines locally 
for justified public health needs.  
 
25 Rwanda- Notification under Paragraph 2(A) of the Decision of 30 August 2003 on the Implementation of Paragraph 6 of 
the Doha Declaration on the TRIPS Agreement and Public Health, IP/N/9/RWA/1 (19 July 2007) at 
http://www.wto.org/english/tratop_e/trips_e/public_health_notif_import_e.htm.  
26 Canada-Notification under Paragraph 2(A) of the Decision of 30 August 2003 on the Implementation of Paragraph 6 of the 
Doha Declaration on the TRIPS Agreement and Public Health, , WTO Doc IP/N/10/CAN/1 (18 October 2007) at 
http://www.wto.org/english/tratop_e/trips_e/public_health_notif_export_e.htm.  
27 Paragraph 2(a) (ii), WTO General Council Decision of 6 December 2005 Amendment of the TRIPS Agreement, 
WT/L/641, (8 Dec. 2005) (Protocol Amending the TRIPS Agreement’ with Annex setting out Article 31bis) at 
http://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm. 
28 Ibid. Appendix to Annexure.  
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D. Licensing Scheme 
Both the Waiver Decision 2003 and proposed Article 31bis detail the procedural and substantive 
requirements that deal with the issuance of compulsory licences by importing and exporting 
countries.  
As an importing country, members from least developing countries are entitled to use the system 
without meeting any notification requirement. Thus, these countries can use the system without 
issuing domestic compulsory licences which is otherwise required under the scheme. Likewise, any 
other Member State, where the desired medicine is not patented, can also use the system without 
issuing a compulsory licence. In all other cases, countries which are willing to use this system must 
issue a compulsory licence prior to importation and it must notify the TRIPS Council of such 
intention.29 The conditions which are generally set out in Article 31 of the TRIPS Agreement 1994 
should be complied with while the countries consider the option of issuing compulsory licence. So 
the solution evolved through the Waiver Decision 2003 and the proposed Article 31bis should be 
construed and applied in conjunction with other substantive requirements of the TRIPS Agreement 
1994 unless specifically waived. The issuance of a compulsory licence itself entails several procedural 
and administrative complications within the overall scheme of the TRIPS Agreement 1994 and it has 
yet to be seen how developing countries will overcome those legal and administrative barriers to 
implement the Waiver Decision 2003 in an effective and efficient way. However, Article 31 does not 
attempt to limit in any way the grounds upon which compulsory licences may be issued and its 
procedural requirements can be incorporated in domestic legislation in a way which would 
supplement the flexibilities designed under Article 31bis.  
Article 31bis also suggests some disclosure obligations on importing country in terms of 
identification of product(s) and expected quantities to be imported. This should be notified to 
the TRIPS Council.30 This aspect has been specifically criticised by some commentators for being 
too restrictive and inhibitive as an exact determination of expected quantity can be unviable 
both practically and economically. Furthermore, no model exists to satisfy such procedural 
requirements and it may put the willing Member States in an unending exercise of monitoring 
and evaluation.31 Some commentators do not consider it a critical obstacle and suggest that the 
proposed Article 31bis does not demand a particular fixed formula, and there are various 
possibilities for complying with this obligation in efficient and innovative ways.32 In order to 
facilitate the usage of complex notification and determination procedure, a World Bank study 
 
29 Ibid. Paragraph 2(a) (iii). 
30 Ibid. Paragraph 2(a) (1). 
31 Rohit Malpani and Mohga Kamal-Yanni, ‘Patent versus Patients: Five Years after the Doha Declaration’, Oxfam 
Briefing Paper (95) at http://www.oxfam.org/en/policy/briefingpapers/bp95_patentsvspatients_061114.  
32 Frederick M. Abbott and Jerome H. Reichman, ‘The Doha Round Public Health Legacy: Strategies for the 
Production and Diffusion of Patented Medicines Under the Amended TRIPS Provisions’ (2007) 10(4) Journal of 
International Economic Law 921-987, 941. 
 Nordic Journal of Commercial Law 
issue 2011#1 
10
in 2005 developed some model forms which Rwanda had used in 2007 to notify the WTO 
about its intention of using Waiver Decision 2003.33  
The proposed Article 31bis and the Waiver Decision 2003 would also regulate the conditions for 
issuing a compulsory licence for exporting Member States.34 The authorised manufacturer from 
the exporting country can only manufacture and export the required quantities which the 
importing country has notified earlier.35 On the insistence of developed countries, the so called 
safeguards against diversion are also enumerated in this regard which requires that the product 
should be clearly identified as having being produced under this system. This may involve 
special packaging, labelling, special shaping or colouring provided that the distinctions are 
feasible and do not significantly affect price.36 Further conditions are put on the licensees to 
post destination and identification information on a website.37  
Non-governmental organisations, international humanitarian organisations and academics have 
criticised the bureaucratic approach of the Waiver Decision 2003 and the Article 31bis.38 A 2006 
report of Médecins Sans Frontières (MSF) notes: 
Prolonged prior negotiations severely limit the ability to use the August 30th Decision 
and act as a disincentive to manufacturers to participate in the process … Anti-diversion 
measures that generic companies must comply with are onerous and are further 
disincentives to their participation in the process.39 
Highlighting the need for a viable and robust supply of pharmaceutical drugs, the report also 
considered the challenging task of manufacturing and supplying under compulsory licensing 
arrangement. In this regard, the MSF report complains that ‘the Decision flies in the face of the 
practical reality of managing a health programme, where flexibility and rapidity of response to 
 
33 Frederick M. Abbott and Rupolph van Puymbroeck, ‘Compulsory Licensing for Public Health, A Guide and 
Model Documents for Implementation of the Doha Declaration Paragraph 6 Decision, World Bank Working 
Paper No. 61 (2005).  
34 Paragraph 2(b) (i), WTO General Council Decision of 6 December 2005 Amendment of the TRIPS Agreement, 
WT/L/641, (8 Dec. 2005) (Protocol Amending the TRIPS Agreement’ with Annex setting out Article 31bis) at 
http://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm. 
35 Ibid. Paragraph 2(b) (i). 
36 Ibid. Paragraph 2(b) (ii). 
37 Ibid. Paragraph 2(b) (iii). 
38 Médecins Sans Frontières, Doha Derailed, A Progress Report on TRIPS and Access to Medicines (Switzerland: MSF 
Campaign for Access to Essential Medicines, 27 August 2003) and Médecins Sans Frontières, Neither Expeditious, 
Nor A Solution: The WTO August 30th Decision Is Unworkable: An illustration through Canada’s Jean Chrétien Pledge to 
Africa (Prepared for the XVI International AIDS Conference, Toronto August 2006), and Oxfam International, 
Patents versus Patients, Five years after the Doha Declaration, Oxfam Briefing Paper 95, November 2006. 
39 Médecins Sans Frontières (MSF), Neither Expeditious, Nor A Solution: The WTO August 30th Decision Is Unworkable: 
An illustration through Canada’s Jean Chrétien Pledge to Africa, Prepared for the XVI International AIDS Conference, 
Toronto, August 2006, 3 
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ever-changing circumstances are vital’.40 Some commentators have suggested that procurements 
strategies can incentivise the potential supplier and such policies can be used to overcome the 
problem of limited demand.41  
E. Remuneration and Non-Authorised Importation 
Article 31bis provides that adequate remuneration need only be paid in the country of export 
by taking into account the economic circumstances of the importing country.42 The system 
requires the importing countries to take reasonable and proportionate measures to prevent 
diversion or re-exportation of medicines supplied under this arrangement.43 The proposed 
Article 31bis obligates Member States to enable patent holders to protect themselves against 
unauthorised importation of pharmaceutical products manufactured under the system, but no 
additional legislative or administrative measures are required in this regard.44  
F. Regional Arrangements 
As the group of least developing countries from Africa was quite instrumental behind the 
development and adoption of the Doha Declaration 2001 because of limited drugs 
manufacturing capacity within the region, the final solution addresses the need of such 
countries in a somewhat specialised and preferential way. The proposed Article 31bis contains a 
special provision for Member States that belong to regional trade agreements of which at least 
half the members are currently least developing countries.45 For such a regional group, a 
relaxation is designed with regard to re-exportation to a member country once the product is 
manufactured and exported to one country under the compulsory licence. However, importing 
countries have not been discharged from the obligation of issuing separate compulsory licences 
where otherwise applicable.46  
 
40 Ibid. 4. 
41 Frederick M. Abbott and Jerome H. Reichman, ‘The Doha Round Public Health Legacy: Strategies for the 
Production and Diffusion of Patented Medicines Under the Amended TRIPS Provisions’ (2007) 10(4) Journal of 
International Economic Law 921-987, 943.  
42 Paragraph 2, WTO General Council Decision of 6 December 2005 Amendment of the TRIPS Agreement, WT/L/641, (8 
Dec. 2005) (Protocol Amending the TRIPS Agreement’ with Annex setting out Article 31bis) at 
http://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm. 
43 Ibid. Paragraph 3. 
44 Ibid. Paragraph 4.  
45 Ibid. Paragraph 3.  
46 Ibid. 
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G. Implementation and Ratification 
The Waiver Decision 2003 was adopted after much deliberation and difficult negotiations and it 
was hoped that it would open a window of opportunities for least developing countries to boost 
their public health coverage programs. With the finalisation of the Protocol of Amendment in 
the form of Article 31bis, commentators were keen to look at the practical aspects of the new 
system as there were a number of concerns regarding the cumbersome nature of the proposed 
solution. To date, thirty-one countries including European Communities have notified their 
acceptance of the proposed amendment of the TRIPS Agreement 1994.47  
However, the export scheme was not used until July 2007 when one least developing country, 
Rwanda, notified its intention to benefit from the scheme set out initially in the Waiver Decision 
2003.48 
The proposed Article 31bis would be rendered permanent in the form of an amendment to the 
TRIPS Agreement 1994 once it is ratified by two-thirds of WTO members. By the December 
2007 deadline, only 13 of 151 WTO countries had ratified it. The WTO pushed back the 
ratification deadline to December 2009 and in the meanwhile, the 2003 waiver remains in 
effect. With thirty-one countries accepting the proposed amendment in September 2010, it is 
anticipated that the Article 31bis would not be included into the TRIPS Agreement 1994 in the 
wake of growing criticism and opposition of civil society organisation, and the situation may 
continue to be governed under the Waiver Decision 2003.49 Moreover, there is some confusion 
about the status of the acceptance notification of the European Communities and individual 
community members have yet to notify their intentions.50  
 
47 These countries include United States (17 December 2005), Switzerland (13 September 2006), El Salvador (19 
September 2006), Rep. of Korea (24 January 2007), Norway (5 February 2007), India (26 March 2007), Philippines 
(30 March 2007), Israel (10 August 2007), Japan (31 August 2007), Australia (12 September 2007), Singapore (28 
September 2007), Hong Kong, China (27, November 2007), China (28 November 2007), European Communities 
(30 November 2007), Mauritius (16 April 2008), Egypt (18 April 2008), Mexico (23 May 2008), Jordan (6 August 
2008) 
Brazil (13 November 2008) Morocco (2 December 2008) Albania (28 January 2009) Macau, China (16 June 2009) 
Canada (16 June 2009) Bahrain (4 August 2009) Colombia (7 August 2009) Zambia (10 August 2009) Nicaragua 
(25 January 2010) Pakistan (8 February 2010) Former Yugoslav Republic of Macedonia (16 March 2010) Uganda 
(12 July 2010); and Mongolia (17 September 2010). See: World Trade Organization, Members Accepting 
Amendment of the TRIPS Agreement (updated 17September 2010) at 
http://www.wto.org/english/tratop_e/trips_e/amendment_e.htm.  
48 World Trade Organization, Members Accepting Amendment of the TRIPS Agreement (17 December 2010) at 
http://www.wto.org/english/tratop_e/trips_e/amendment_e.htm.  
49 Ibid. 984.  
50 Matthew Kennedy, When Will the Protocol Amending the TRIPS Agreement Enter into Force? (2010) 13(2) 
Journal of International Economic Law 459-473.  
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Most of the non-governmental organisations, humanitarian agencies and independent experts 
consider the system is defective in its design and modalities and it is extremely difficult for 
potential Member States to invoke it to meet their public health needs.51 They maintain that 
conditions associated with the issuance of licences, notification requirements, the so-called 
safeguard clause and anti-diversion measures have unnecessarily over-burdened the system and 
it is very hard for least developing countries to overcome these barriers. James Love of the 
Consumer Project on Technology wrote about the Waiver Decision 2003: ‘The new agreement 
has very modest benefits, and it has very substantial costs, risks and uncertainties.’52 
This view is further augmented by the European Generic Medicine Association (EGA) 
declaring that WTO compulsory licensing system is unworkable and will not improve access to 
medicine. Mr Greg Perry, Director General of the EGA expressed his views recently at the 
WTO Public Forum 2008 and said: ‘The WTO’s 2003 August 30 Decision concerning 
compulsory licenses is complicated, unworkable and unable to deliver any significant 
improvement in access to medicines.’53 
However, Frederick Abbott and Jerome Reichman construe the terms of the new system in a 
positive way suggesting that a better trade-off deal was practically not possible given the political 
and structural environment of trade negotiations at that time. They consider that most of the 
procedural requirements set out in the new system can be intelligently managed within national 
laws and willing Member States can overcome potential problems through pooled procurement 
strategies and innovative decision-making.54  
However, in the light of theoretical analysis and the two cases (Rwanda and India), it is hard to 
construe the Waiver Decision 2003 as a positive measure which can solve the problem of access 
to medicine. The decision is cumbersome and rigid and beyond its textual constraints, it also 
restricts the economic incentive which is essential to maintaining a manufacturing base.  
 
51 MSF Access to Medicines Campaign, Doha Derailed, A Progress Report on TRIPS and Access to Medicines, 27 August 
2003 and Neither Expeditious, Nor A Solution: The WTO August 30th Decision Is Unworkable: An illustration through 
Canada’s Jean Chrétien Pledge to Africa, Prepared for the XVI International AIDS Conference, Toronto, August 
2006, and Oxfam International, Patents versus Patients, Five years after the Doha Declaration, Oxfam Briefing 
Paper 95, November 2006.  
52 James Love, ‘CPTech Statement on WTO Deal on Exports of Medicines’, August 30, 2003 at 
http://www.cptech.org/ip/wto/p6/cptech08302003.html.  
53 European Generic Medicine Association, ‘WTO Compulsory Licenses System is Unworkable and Will Not 
Improve Access to Medicines’ (Press Release 25 September 2008, Brussels at http://www.egagenerics.com/pr-2008-
09-25.htm 
54 Frederick M. Abbott and Jerome H. Reichman, ‘The Doha Round Public Health Legacy: Strategies for the 
Production and Diffusion of Patented Medicines Under the Amended TRIPS Provisions’ (2007) 10(4) Journal of 
International Economic Law 921-987, 941. 
 Nordic Journal of Commercial Law 
issue 2011#1 
14
IV. Indian Compulsory Licensing Regime 
After the series of sporadic amendments, India finally brought its patent law into conformance 
with the TRIPS Agreement 1994 through the Patents (Amendment) Act 2005 (India). It is important 
to see that India has incorporated the spirit of the Waiver Decision 2003 in its domestic law to 
facilitate the smooth flow of generics export to other countries. The Waiver Decision 2003 is 
merely an international instrument and its real potential will be demonstrated once put into 
operation under domestic laws and regulations. Through the Patents (Amendment) Act 2005 
(India), India has supposedly provided some robust and strong compulsory licensing avenues 
which yet need to be tested practically to judge its effectiveness.  
The principal provisions dealing with compulsory licensing consist of Section 84, Section 92 
and Section 92A of the Patents Act 1970 (India). In addition to this, Section 11A also provides a 
mechanism for automatic compulsory licensing in certain cases. Here, I am focusing on the 
compulsory licensing provision relevant to pharmaceutical exports.  
A. Section 92A: Doha Style Compulsory Licence 
The Patents (Amendment) Act 2005 (India) introduces a third compulsory licensing avenue which 
reflects the WTO Waiver Decision 2003 in domestic law. Section 92A provides for compulsory 
licences to enable exports of pharmaceutical products to those countries with no manufacturing 
capacity of their own. It states that: 
Compulsory licence shall be available for manufacture and export of patented 
pharmaceutical products to any country having insufficient or no manufacturing 
capacity in the pharmaceutical sector for the concerned product to address public health 
problems, provided compulsory licence has been granted by such country or such 
country has, by notification or otherwise, allowed importation of the patented 
pharmaceutical products from India. The Controller shall, on receipt of an application 
in the prescribed manner, grant a compulsory licence solely for manufacture and export 
of the concerned pharmaceutical product to such country under such terms and 
conditions as may be specified and published by him.55 
This Section also defines the term ‘pharmaceutical product’ in line with the language of the 
Waiver Decision 2003 and the proposed Article 31bis and includes ‘any patented product, or 
product manufactured through a patented process, of the pharmaceutical sector needed to 
address public health problems and shall be inclusive of ingredients necessary for their 
 
55 Section 92A(1) and (2) of the Patents Act 1970 (India). 
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manufacture and diagnostic kits required for their use.’56 An application for the grant of a 
compulsory licence under this Section can be filed at any time after a patent has been issued.57 
Section 92A provides a relatively flexible and fast track Doha style licensing mechanism in view 
of the Waiver Decision 2003 and the adoption of subsequent national laws in many Member 
States such as Canada, China, Norway and the European Union. It necessarily reflects the spirit 
of the Waiver Decision 2003 and employs a less restrictive language and procedural requirements 
to issue a compulsory licence. For instance, Indian law does not explicitly require as a pre-
condition that an importing country should have issued a licence before Indian law comes into 
action, and it merely puts the condition of a notification or otherwise to allow exportation of 
patented medicines. This provision was first introduced through the Patents Ordinance 2004 
(India) and at that time it required that the exporter obtain a compulsory licence from the 
importing country as well.58 However, this requirement was later dropped to accommodate 
situations where no such patent exists in the importing country and a notification would suffice 
in such cases.  
The Section is completely silent about the requirements of specifying the amount of 
pharmaceutical products that will be manufactured under compulsory licence which is an 
important procedural aspect of the Waiver Decision 2003. Likewise, no requirements are 
mentioned with regard to separate packaging, colouring or shape. It is important to note that 
no such guidelines are currently under consideration when the Indian Patent Office is 
finalising its Manual of Patent Practice and Procedure.59 This particular Section was scrutinised 
recently when the Indian generic manufacturer Natco applied for a compulsory licence for 
Roche’s patented medicine, erlotinib, for export to Nepal.  
B. Section 11A: Automatic Compulsory Licences 
India was among those developing countries which opted to enjoy the full transition period 
allowed under the TRIPS Agreement 1994. Thus until 2005, India was not granting product 
patents for pharmaceutical and agro-chemical products and, in lieu, it had established a 
mailbox mechanism to determine priority matters in the post-2000 scenario. By virtue of this 
mailbox facility, applications would be judged for ‘novelty’ on the basis of the filing date and 
 
56 Ibid. Explanation.  
57 Ibid. No post grant waiting period is maintained under this Section unlike Section 84 of the Act.  
58 Shamnad Basheer, ‘Indian Tryst with TRIPS: The Patents 9Amendment) Act 2005’ (2005) 1(1) The Indian 
Journal of Law and Technology 15-46, 28. 
59 Intellectual Property India, Draft Manual of Patent Practice and Procedure at 
http://www.patentoffice.nic.in/ipr/patent/DraftPatent_Manual_2008.pdf 
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not with reference to 2005, the year in which product patents were first incorporated into the 
patent regime. The Patents (Amendment) Act 2005 (India) provides that where a patent is granted 
to any of those mailbox applications, an automatic compulsory licence would issue to those 
generic companies that made a ‘significant investment’ and were ‘producing and marketing’ a 
drug covered by the mailbox application prior to 2005. Such licence is subject to the payment 
of a reasonable royalty.60 
There has been much discussion about the Indian compulsory licensing regime and a range of 
positions can be identified in this regard. First, the Pharmaceutical Research and Manufacturer 
of America (PhRMA) in its 2008 submission to USTRA termed the Indian compulsory 
licensing provisions as one of the most damaging provisions of the Indian Patent Law.61 
Second, some commentators consider that the Indian export oriented compulsory licensing 
regime is the broadest in scope when compared with other jurisdictions and thus ‘widespread 
use of the Section 92A avenue for compulsory licensing to export patented medicines appears 
likely’.62  
However, I would argue here that the Indian compulsory licensing provisions under Section 
92A should be understood and analysed both in a legal and factual context. A study 
undertaken for WHO shows that very few Indian pharmaceutical companies think that the 
Indian patent law provides an economically lucrative option for them to retain their export 
sales. Of the 103 firms, only 25 firms thought it was an economically lucrative option, whereas 
78 firms did not think so. It is important to note that out of 25 firms which responded 
positively, only 6 firms have a strong technological base to meet export market demand on a 
sustainable basis.63 
V. Tarceva and Sutent Compulsory Licences  
The Indian compulsory regime has been tested by two separate compulsory licence applications 
for anti-cancer medicines involving erlotinib and sutent.  
 
60 Section 11A Proviso of Patents Act 1970 (India). 
61 Pharmaceutical Research and Manufacturer of America, ‘Special 301 Submission 2008’, February 11, 2008, 68, 
at http://www.ustr.gov/assets/Trade_Sectors/Intellectual_Property/Special_301_Public_Submissions_2008/
asset_upload_file109_14495.pdf 
62 Janice M. Mueller, ‘The Tiger Awakens: The Tumultuous Transformation of India’s Patent System and the Rise 
of Indian Pharmaceutical Innovation’ (2007) 68 University of Pittsburgh Law Review 491-641, 604 at 
http://lawreview.law.pitt.edu/issues/68/68.3/Mueller.pdf 
63 Padmashree Hehi Sampath, ‘Economic Aspects of Access to Medicines after 2005: Product Patent Protection 
and Emerging Firm Strategies in the Indian Pharmaceutical Industry’ Institute of New Technologies, United 
Nations University at http://www.who.int/intellectualproperty/studies/PadmashreeSampathFinal.pdf 
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A. Erlotinib hydrochloride 
Erlotinib which is marketed by Genentech, OSI Pharmaceuticals and Roche in different parts 
of the world under the brand name Tarceva, is prescribed for the treatment of non-small cell 
lung cancer and pancreatic cancer. It is basically a small molecule human epidemic growth 
factor type 1/epidermal growth factor receptor inhibitor which was approved in November 
2004 by the U.S. Food and Drug Administration (FDA).64 The drug is primarily developed by 
OSI Pharmaceuticals and later business and marketing partnerships were developed with 
Genentech and Roche. Now OSI Pharmaceuticals and Genentech are marketing the Tarceva 
brand in the United Sates, and elsewhere it is marketed by Roche. After its marketing approval 
in 2004, Tarceva did quite well in the global oncology market by generating substantial revenue 
for marketing companies.  
In its Business Report 2007, the Roche Group declared Tarceva among its top selling 
pharmaceutical products with sales of 1,062 million Swiss Francs. The Report indicates a 31% 
annual increase in sales.65 Genentech markets this drug jointly with OSI Pharmaceutical and in 
2007 it reported US $417 million sales with a steady annual growth since 2006.66 For OSI 
Pharmaceuticals, Tarceva stands as the single most important drugs for business and revenue 
purposes. In 2007, it reported revenues of $340 million (up 41% on the prior year) and it was 
observed: 
The business continues to be anchored around our flagship anti-cancer therapy 
Tarceva® which, just three years after the November 2004 approval in non-small cell 
lung cancer (NSCLC), exited the year with fourth quarter global sales of $250 million – 
an annualized run-rate of $1 billion, the recognized industry-wide metric of a 
blockbuster.67 
B. Tarceva Patents 
OSI Pharmaceuticals and Roche secured the patents of erlotinib (the active pharmaceutical 
ingredient of Tarceva) in the United States, Europe, Japan, and number of other countries. 
Indeed, Roche claimed in India that patents related to Tarceva had already been filed in more 
 
64 U.S. Food and Drug Administration Consumer Information at http://www.fda.gov/cder/
consumerinfo/druginfo/Tarceva.HTM. 
65 Roche, Annual Report 2007: We Innovate Healthcare (Switzerland: 2007), 19 at http://www.roche.com/gb07e.pdf. 
66 Genentech, Annual Report 2007: In Business for Life (California: 2007) 23, at http://www.gene.com/gene/
about/ir/historical/annual-reports/2007/2007annualreport.pdf 
67 OSI Pharmaceuticals, Annual Report 2007 (New York: 2007) 1, at http://media.corporate-
ir.net/media_files/irol/70/70584/2007_OSIP_Annual_Report.pdf 
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than 80 countries and in almost 50 countries it was granted.68 In the United States, the Orange 
Book data shows two patents related to Tarceva which would respectively expire on March 30, 
2015 (Patent No. 5747498) and November 9, 2020 (Patent No 6900221).69 In addition to this, 
OSI Pharmaceuticals was granted patent term extension certificates which extend the United 
States patent to November 2018 and a corresponding patent in Europe to March 2020.70 
Further patenting activity is expected around erlotinib given its emerging importance and 
ongoing research regarding the possibility of future use of the same molecule for pipeline 
products. OSI Pharmaceuticals states in this regard: 
We are also currently pursuing U.S. and international patents for new inventions 
concerning various other formulations of erlotinib and related intermediate chemicals 
and processes in an effort to enhance our intellectual property rights in this compound. 
We have obtained a patent covering a key polymorphic form of Tarceva in the United 
States, which expires in 2020. We are also currently seeking patent protection for 
additional methods of use for Tarceva, including the use of Tarceva in combination 
with other compounds.71 
In India, Pfizer Inc. USA and OSI Pharmaceuticals jointly filed an erlotinib patent application 
on 30th March 1995. The invention claimed in the patent application was related to 
‘Quinazoline Derivatives Compounds and Composition thereof’ with initially 27 claims.72 It is 
worthwhile mentioning that the corresponding US patents showed a broader claim strategy 
where 79 claims were made under United States Patent No. 6,900,221.73 The other US patent 
related to erlotinib contains 32 claims.74 However, realising the very broad scope of claims made 
in Patent No. 5,747,498 which may become ultimately susceptible to challenge under 
 
68 F. Hoffmann-La Roche Ltd v Cipla (I.A 642/2008 IN CS (OS) 89/2008) dated March 19 2008, paragraph 65, Full 
text is available at: http://courtnic.nic.in/dhcorder/dhcqrydisp_j.asp?pn=1031&yr=2008. 
69 Approved Drug Products with Therapeutic Equivalence Evaluations in Electronic Orange Book at 
http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021743&Product_No=001&tabl
e1=OB_Rx  
70 OSI Pharmaceuticals Annual Report 2007, 12, at http://media.corporate-ir.net/media_files/irol/
70/70584/2007_OSIP_Annual_Report.pdf 
71 Ibid.  
72 Decision of Assistant Controller of Patents and Designs in the matter of patent application No. 537/Del/1996 
at https://210.210.88.164/patentdecisionsearch/display_uploaded.asp?application_number=537-DEL-1996-154 
73 Norris, Timothy et al (2005), ‘Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-




74 Schnur, Rodney Caughren (1998), ‘Alkynyl and azido-substituted 4-anilinoquinazolines’ United States Patent 
No: 5,747,498 at http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l
=50&s1=5747498.PN.&OS=PN/5747498&RS=PN/5747498 
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Paragraph IV procedure of the Drug Price Competition and Patent Term Restoration Act (Hatch-
Waxman Act), OSI Pharmaceuticals filed an application in February 2008 to the United States 
Patent and Trademark Office to correct certain claims by deleting surplus compounds from the 
claims.75  
The Indian Patent Office had already raised these objections with regard to the erlotinib patent 
application and on 22 January, 2006, eleven preliminary objections were raised in the First 
Examination Report of the Indian Patent Office including the lack of novelty and the inventive 
step.76 These objections were later removed and finally the applicants managed to secure a 
patent on the following two claims: 
1. A novel [6,7-bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl) amine 
hydrochloride compound of the formula A, and 
2. A process for preparing the compound as claimed in claim 1.77 
C. Pre-Grant Opposition by Natco Pharma 
After the case was put for the final grant of patent, Natco Pharma Ltd., a local generic 
manufacturer, filed an opposition to the grant of patent on 10th April 2007. This application 
was made under Section 25(1) of the Patents Act 1970 (India) which deals with pre-grant 
opposition proceedings. The grounds on which pre-grant opposition may be based include 
virtually all patentability criteria including anticipation, lack of inventive step and non-
invention.78 In its opposition petition, Natco Pharma mainly raised concerns about whether the 
application was non-obvious, and whether there had been sufficient disclosure of the invention 
in the specifications.79  
In view of these objections, the Indian Patent Office examined the question of the novelty and 
inventive step again in the light of prior art citation EP 0566226, published on 20.10.93 and 
EP 0520722 published on 30.12.92. In the end, it decided that none of the citations were 
specific for the claims made under the patent application. The opponent maintained that the 
 
75 OSI Pharmaceuticals Annual Report 2007, 12, at http://media.corporate-ir.net/media_files/irol/70/
70584/2007_OSIP_Annual_Report.pdf 
76 Decision of Assistant Controller of Patents & Designs in the matter of patent application No. 537/Del/1996, 11. 
Full text available at https://210.210.88.164/patentdecisionsearch/display_uploaded.asp?application_number=537-
DEL-1996-154. 
77 Ibid. 13. 
78 Section 25 (1) a-k of the Patents Act 1970 (India). 
79 Decision of Assistant Controller of Patents & Designs in the matter of patent application No. 537/Del/1996, 14. 
Full text available at https://210.210.88.164/patentdecisionsearch/display_uploaded.asp?application_number=537-
DEL-1996-154. 
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claimed invention was an obvious derivative derived from 4-Anilinoquinazoline nucleus and 
‘the combination of simple functional groups like alkoxy, alkyl, alkynyl, halo to already known 
basic nucleus or compound is obvious to a person of ordinary skill in the art’.80 Applicants also 
survived the attack on their claims on the basis of Section 3(d) of the Patents Act 1970 (India) by 
showing the data regarding survival rate increase by the use of drug. The Patent Office decided 
in favour of applicants and the patent was granted accordingly against two claims agreed during 
the proceedings.  
During the hearings, the parties could not agree on the nature of opposition proceedings with 
Natco considering it as a pre-grant opposition under Section 25(1) and OSI Pharmaceuticals 
and others as a post-grant opposition under Section 25(2). This confusion basically arose 
because of an earlier decision by the Patent Office on its own objections and the subsequent 
order for the grant of patent which was delayed due to internal processes. This distinction is 
important from the point of view of the possibility of filing a post-grant opposition, though 
Natco could not succeed in its pre-grant opposition. On this point, the Patent Office decided 
that the proceeding was a pre-grant opposition.81 The success in pre-grant opposition was an 
important victory for OSI Pharmaceuticals and other parties and its Annual Report 2007 states: 
‘A patent corresponding to the U.S. composition of matter patent for Tarceva was granted in 
February 2007 in India and we, along with our collaborator Roche, successfully opposed a pre-
grant opposition by Natco Pharma, Ltd. of Mumbai, India in July 2007.’82 
D. Sunitinib Malate 
Sunitinib Malate is prescribed for the treatment of renal cell carcinoma, a type of kidney 
cancer. It is manufactured and marketed by Pfizer under the brand name sutent and also used 
for the treatment of gastrointestinal stromal tumour (GIST). GIST is a cancer of the stomach 
and bowels which is caused by the uncontrolled growth of cells in the wall of the stomach or 
bowel. Sutent was the first medicine approved by the U.S. Food and Drug Administration 
(FDA) simultaneously for two indications. While approving the drug in January 2006, Steven 
Galson, Director of FDA’s Center for Drug Evaluation and Research, observed: ‘Today’s 
approval is a major step forward in making breakthrough treatments available for patients with 
rare and difficult to treat forms of cancer.’83 
 
80 Ibid. 19. 
81 Ibid. 26. 
82 OSI Pharmaceuticals Annual Report 2007, 13, at http://media.corporate-ir.net/media_files/irol/70/
70584/2007_OSIP_Annual_Report.pdf 
83 U.S Food and Drug Administration, ‘FDA Approves New Treatment for Gastrointestinal and Kidney Cancer’, January 
26, 2006, P06-11 at http://www.fda.gov/bbs/topics/news/2006/NEW01302.html 
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In Pfizer’s product portfolio, sutent is still categorised as one of the new medicines which is 
performing very well with an increase of 166% in sales revenue during 2006.84 Sutent’s sales 
revenue increased to US$581 million in 2006 and that was mainly because of its widespread 
and speedy marketing approval in Europe and many Asian countries.  
E. Sutent Patents 
In the United States, three patents were granted for sunitinib malate which would expire on 
February 15, 2021 (Patent No. 6573293 and Patent No. 7125905) and December 22, 2020 
(Patent No. 7211600). In addition to this, a New Chemical Entity (NCE) exclusivity protection 
is also applicable until January 26, 2011.85 A PCT application (Application No. 
PCT/US1999/012069) was also filed in 1999 and the patents were granted in several 
designated countries between 2001 and 2005.86 The parallel Indian patent application was filed 
on August 9, 2002 under the title of Pyrrole Substituted 2-Indolinone Protein Kinase Inhibitors 
and a patent was granted on August 31, 2007.87 This patent (Patent No. 209251) was granted 
jointly to Sugen Inc. and Pharmacia & Upjohn Company. Sugen was a small California based 
biotechnology company which was acquired by Pharmacia & Upjohn Company in the late 
1990s and subsequently Pharmacia & Upjohn Company was acquired by Pfizer in 2003. 
However, Pfizer kept using these distinct business identities as a business strategy.88 
Patent protection is central in Pfizer’s business strategy and one of its foremost business 
strategies is to refocus and optimise its patent protected portfolio.89 In its Annual Review of 
2007, Pfizer declared: ‘We are refocusing and optimizing our patent-protected portfolio to 
speed up the flow of new products, invest more in areas of strength, and deliver greater value to 
customers and patients.’90 In this context, an attempt to secure compulsory licences for these 
two drugs was really seen as an offensive move by the patent owners and both applications were 
fiercely contested in the patent office.  
 
84 Pfizer, Annual Review 2007 (New York: 2007) 7 
http://media.pfizer.com/files/annualreport/2007/annual/review2007.pdf 
85 Approved Drug Products with Therapeutic Equivalence Evaluations in Electronic Orange Book at 
http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021938&Product_No=001&tabl
e1=OB_Rx 
86 Tang, Peng Cho et al (Filed in 1999), ‘Pyrrole Substituted 2-Indolinone Protein Kinase Inhibitors’, PCT 
Application No: PCT/US1999/012069 at http://www.wipo.int/pctdb/en/wo.jsp?WO=1999061422&IA=
US1999012069&DISPLAY=STATUS 
87 Government of India, Controller General of Patents Designs and Trademarks at 
https://124.124.220.66/patentgrantedsearch/(S(k3gh1m55vis3y1rkuwtxcx55))/GrantedSearch.aspx.  
88 Pfizer Annual Review 2007, 14, http://media.pfizer.com/files/annualreport/2007/annual/review2007.pdf.  
89 Ibid. 4.  
90 Ibid. 12.  
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F. Natco’s Compulsory Licence Application 
Notwithstanding the unsuccessful attempt to block the erlotinib patent through a pre-grant 
opposition procedure, Natco Pharma Ltd. applied for compulsory licences under Section 92A 
of the Patents Act 1970 (India). As mentioned earlier in this chapter, Section 92A provides the 
avenue for the grant of a Doha style compulsory licence solely for export purpose. In early 
January 2008, Latha Jishnu of the Business Standard reported that: 
[T]he first application for a compulsory licence filed in India, has put a key provision of 
the Indian Patents (Amendment) Act, 2005 under the scanner. The application has 
been filed by Natco Pharma of Hyderabad for Roche’s erlotinib (brand name Tarceva), 
which is used in the treatment of lung cancer.91 
In its application to the Patent Office for the grant of a compulsory licence under Section 92A, 
Natco asked for permission to manufacture 30,000 tablets of Tarceva for export to Nepal 
against a fixed royalty of 5%. Later, it was also reported that Natco applied for a compulsory 
licence of Sunitinib against the same terms and conditions.92 
G. Nepal: Public Health Profile and Access to Medicines 
Nepal is a least developing country in South Asia having boundaries with China in the north 
and India in the south. With a population of 27,641,000 its gross national income per capita is US$1,010.93 The 
share of annual health expenditure as a percentage of the national budget was 5.1% in 2001-03. 
Nepal’s rank in terms of the UNDP Human Development Index (HDI) is 142 among 177 
countries.94 
There have been a number of estimates of cancer incidence in Nepal. Some estimates show that 
the incidence of cancer is approximately 120 per l00,000 head of population, and it is assumed 
that there are 35,000 to 40,000 cancer sufferers in the country.95 The incidence of cancer is 
thought to be rising every year. The hospital based statistics showed that there were 23% cases 
with malignancies in 1993 compared to 19% in 1989. The five most common malignant 
 
91 Latha Jishnu, ‘Cancer drug puts licence, patent rules to test’, Business Standard, January 16 2008, at 
http://in.rediff.com/money/2008/jan/16drug.htm 
92 Tatum Anderson, ‘India Considers Compulsory Licences For Exportation of Drugs’, Intellectual Property Watch, 
20 February 2008, at http://www.ip-watch.org/weblog/index.php?p=933 
93 World Health Organization Country Statistics at http://www.who.int/countries/npl/en/ 
94 World Health Organization, ‘2007/2008 Human Development Index rankings’ at 
http://hdr.undp.org/en/statistics/.  
95 Sunil Kumar Joshi, ‘Occupational Cancer in Nepal – An Update’ (2003) 1(2) Kathmandu University Medical 
Journal 144-151, 144 at http://member.wnso.org/drsunilkj/Occupationalcancer.pdf 
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diseases in Nepal are bronchial cancer, breast cancer, cervical and ovarian cancer, stomach and 
colorectal cancer and leukaemia.96 The Nepal pharmaceutical industry is largely dependent 
upon the Indian market and most of local manufacturers are importing their raw materials 
from India and China (see Table 4.2)  
Table 1.2: Top 15 Suppliers to Nepal 
Rank Company Origin Value 
(in crore) 
Market Share  
(%) 
1 Nepal Pharma  Nepal 13.2 3.85 
2 Lomus Pharma Nepal 11.8 3.47 
3 Aristo Indian 11.4 3.31 
4 Deurali Janata Nepal 10.7 3.08 
5 Knoll Pharma MNC 9.6 2.78 
6 Dabur Indian 9.1 2.65 
7 Lupin Indian 8.7 2.50 
8 National Health Care Nepal 8.6 2.50 
9 Hoechst MNC 8.1 2.35 
10 Alkem Indian 7.8 2.27 
11 Ranbaxy Indian 7.4 2.14 
12 Cadila Pharma Indian 6.3 1.84 
13 Cadila Health Care Indian 6.3 1.83 
14 E Merck  MNC 6.0 1.75 
15 Novartis MNC 5.6 1.64 
Source: Dr R. K. Srivastava97 
Nepal joined the WTO on April 23, 200498 and it is regarded as at least a developing country 
for implementation and enforcement of various treaty related obligations including the TRIPS 
Agreement 1994. Historically, Nepal had domestic intellectual property laws but it had to amend 
those laws in the light of obligations of the TRIPS Agreement 1994 by January 1, 2006.99 This is 
 
96 Ibid.  
97 Dr R. K. Srivastava, ‘Nepal-New Emerging Pharma Market’ (undated) http://www.p-m-
c.com/PMC%20WEB%20_articles/Nepal%20New%20Emerging%20Pharma%20Market.doc 
98 World Trade Organization, ‘Member Information: Nepal and WTO’ (accessed on September 13, 2010) at 
http://www.wto.org/english/thewto_e/countries_e/nepal_e.htm 
99 World Trade Organization, ‘WTO Ministerial Conference Approves Nepal’s Membership’ (accessed on 
September 13, 2010) at http://www.wto.org/english/news_e/pres03_e/pr356_e.htm 
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of course subject to the Doha Declaration’s extended deadline for least developing countries to 
apply provisions on pharmaceutical patents until 1 January 2016.100 
As a least developing country, Nepal has as yet no obligation to protect pharmaceutical 
products under patent law. According to the Patent, Design and Trademark Act 1965 (Nepal), a 
patent is defined as ‘any useful invention relating to a new method or process of manufacture, 
operation or publicity of any material or a combination of materials, or that made on the basis 
of a new theory or formula’.101A patent is valid only for 15 years after registration.102 There has 
been a little patenting activity in Nepal and only 49 Patents were registered until 2002.103 
Natco’s compulsory licensing applications have generated substantial debate in India and 
elsewhere but surprisingly there is complete silence from Nepal. Though these compulsory 
licenses were intended to be used for export to Nepal but we can see virtually no debate in 
Nepal about this issue. With the status of a least developing country, Nepal has no obligation to 
respond to this situation with a domestic compulsory license and its mere notification should 
suffice in the given circumstances. In fact, there is no compulsory licensing related provision in 
the Patent, Design and Trademark Act 1965 (Nepal). However, for a successful outcome of Natco’s 
application in India, at least two factors are important in Nepal. First, Nepal should determine 
and establish its public health need with regard to products which Natco is attempting to 
manufacture under compulsory license. Second, Nepal should notify the WTO about its 
intention to invoke the Waiver Decision 2003, much like Rwanda  
Natco’s attempt looks half-hearted and apparently it rushed to the patent office without 
adequate preparation. These points were justifiably highlighted by the patentees before the 
patent office and played a decisive role in the final outcome. The matter is further discussed in 
subsequent sections. Pfizer’s presence in Nepal and its pricing policy there is another aspect of 
this debate which is not discussed by the commentators. Aiming clearly to counter Natco’s 
compulsory licensing application, Pfizer announced the launch of a free sutent access program 
in Nepal.104 The decision was first revealed in April 2008, much later than the filing of the 
compulsory licensing applications in India.  
 
100 World Trade Organization, ‘The Doha Declaration Explained’ (accessed on September 13, 2010) at 
http://www.wto.int/english/tratop_e/dda_e/dohaexplained_e.htm 
101 Section 2(a) of the Patent, Design and Trade Mark Act, 1965 at http://www.vakilno1.com/
saarclaw/nepal/patentandtrademarkact/chapter1.htm 
102 Section 8 (1) of the Patent, Design and Trade Mark Act, 1965 at http://www.vakilno1.com/saarclaw/
nepal/patentandtrademarkact/chapter1.htm.  
103 Sirjana Sharma, ‘Intellectual Property Law’ on Nepalese Lawyers in the US (January 11, 2008) at 
http://anlus.wordpress.com/2008/01/11/article-intellectual-property-law/ 
104 C.H. Unnikrishnan, ‘Pfizer to launch free Sutent access programme in Nepal; The Wall Street Journal, April 3, 
2008 at http://www.livemint.com/2008/04/03004838/Pfizer-to-launch-free-Sutent-a.html?d=1 (Note that ‘The 
move may upset Indian generic drug maker Natco Pharma Ltd’s efforts to secure a compulsory licence for 
exporting copy-cat versions of the drug’.) 
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H. Procedural Requirements 
In contrast to the Doha Declaration 2001 and the Waiver Decision 2003, Section 92A adopts a 
straightforward and relatively fast track mechanism to issue a compulsory licence for export 
purposes. This provision does not stipulate the requirement of issuance of two back-to-back 
compulsory licences in importing and exporting countries along with separate notification 
obligations. In fact, the provision is silent about the royalty payment and no formula is referred 
for its calculation. However, the Patent Controller is authorised under the relevant provision to 
determine the terms and conditions of such licence.  
Despite the gaps in Section 92A, it is important to note that the whole scheme is designed to 
meet the obligations of the Doha Declaration 2001 and any interpretation of this section should 
be construed against this background. In light of the Doha Declaration 2001 and related 
provisions of Indian law, Natco’s application can be analysed in the following way. 
According to the Doha Declaration 2001, an importing country is obliged to notify the Council 
for TRIPS about the name and expected quantity of the drug which it intends to import under 
the scheme. The Declaration further requires that the member state must establish beforehand 
that it has virtually no, or a very limited, manufacturing capacity with regard to the drug which 
it wants to import and it should issue a compulsory licence if the product is patented in that 
importing country. In this case, Nepal is a least developing country and it does not need to 
establish its insufficient manufacturing capacity pursuant to the Doha Declaration 2001. Given 
that Nepal has no product patent regime, issuing a compulsory licence has no relevance. 
However, general notification of intent to the Council for TRIPS is required which Nepal has not 
made. In the very first Doha-style compulsory licensing case, Rwanda had notified its intention 
to use the mechanism of the Doha Declaration 2001.105 
It is unclear how the Indian Patent Office will operate in the absence of such a notification to 
the Council for TRIPS. Nepal has only reportedly issued an import letter in favour of Natco. The 
contents of this letter which was issued from the Nepalese Ministry of Health are not yet known 
so its adequacy in terms of satisfying the procedural requirement of Doha Declaration 2001 is yet 
to be established. This point was precisely raised by the patentees during a hearing before the 
Patent Office and an objection was raised as following: 
Counsel for patentees further argued that the “notice” by the Nepal government that 
Natco was relying upon was insufficient to amount to a formal notification of an intent 
to import drugs produced under a compulsory licence. He alleged that Natco, in its 
application for a compulsory licence, had merely submitted a letter from the Nepal 
government recommending that one consignment of erlotinib be approved for import 
 
105 Rwanda- Notification under Paragraph 2(A) of the Decision of 30 August 2003 on the Implementation of Paragraph 6 of 
the Doha Declaration on the TRIPS Agreement and Public Health, IP/N/9/RWA/1 (19 July 2007) at 
http://www.wto.org/english/tratop_e/trips_e/public_health_notif_import_e.htm 
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from India during the period 2006-2007. He argued that this was insufficient to 
demonstrate Nepal’s intent to utilise the 30 August mechanism to import drugs 
produced under a compulsory licence. In contrast, he pointed to the formal notification 
provided to the WTO by Rwanda of its intent to utilise the paragraph 6 
implementation.106 
Setting aside the procedures of the Doha Declaration 2001 for a moment, Natco can argue that 
Indian law does not prescribe the requirement of notification to the Council for TRIPS and any 
document establishing the intent of the importing country should be considered satisfactory.  
Indeed, a bare reading of Section 92A supports this assertion as it states: 
Compulsory licence shall be available for manufacture and export of patented 
pharmaceutical products to any country having insufficient or no manufacturing 
capacity in the pharmaceutical sector for the concerned product to address public health 
problems, provided compulsory licence has been granted by such country or such 
country has, by notification or otherwise, allowed importation of the patented 
pharmaceutical products from India.107 (emphasis added) 
Once the importing member country fulfils the requirement, then the exporting country can 
issue a compulsory licence under its domestic law. In this case Natco has applied to the Patent 
Office after securing a letter from Nepal stating its intent, the name of the product, required 
quantities and a royalty offer. This licence is necessary in India given the existence of a valid 
patent by OSI Pharmaceuticals and Pfizer.  
In the absence of any notification from Nepal, it is difficult to determine the prevalence of a 
public health problem and its nature. Paragraph 1 of the Doha Declaration 2001 clearly spells 
out the intent by linking it with public health problems. It is not necessary for Nepal to show a 
national emergency before importing drugs from India under the Indian compulsory licence 
but such an action should definitely be related to a public health problem. The relevance of an 
anti-cancer drug contrary to an HIV/AIDS treatment may become a contentious point as we 
have already seen this line of argument the case of Thailand.108 
 
106 Chan Park, ‘Natco’s application for CL for Export – Hearing in the Delhi Patent Office’ on Commons-Law Blog 
(March 20, 2008) at http://commonslaw.freeflux.net/blog/archive/2008/03/20/commons-law-natco-s-application-
for-cl-for-export-hearing-in-the-delhi-patent-office.html 
107 Section 92A(1) and (2) of the Patents Act 1970 (India). 
108 Jonathan Burton-MacLeod, ‘Tipping point: Thai Compulsory Licences Redefine Essential Medicines Debate’ in 
Thomas Pogge, Matthew Rimmer and Kim Rubenstein (eds), Incentives For Global Public Health: Patent Law and 
Access to Essential Medicines (Cambridge University Press: 2010) 77. Also see: Office of the United States Trade 
Representative, 2009 Special 301 Report (April 30, 2009) 21 at 
http://www.ustr.gov/sites/default/files/Full%20Version%20of%20the%202009%20SPECIAL%20301%20REP
ORT.pdf 
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I. The Right to a Hearing 
In response to Natco’s application, Pfizer approached the Patent Office to contest the matter 
both on its merits and on procedural grounds. Indeed, the Patent Office itself identified some 
lacunas in Natco’s application and those were communicated to the applicant. Natco 
responded to those points and maintained that patentees had no right to be heard in this case. 
On the questions of maintainability of this application and the patentees right to become a 
party, two hearings were held and finally the Patent Office resolved this matter to the extent of 
a hearing right in favour of patentees. 
It is pertinent to note that Section 92A of the Patents Act 1970 (India) is silent on the question 
of a patent holder’s right to a hearing and relevant rules along with draft Manual of Patent 
Practice and Procedure are equally unhelpful in this regard. Natco interprets it as a fast track 
compulsory licensing avenue unlike other provisions and asserts that a hearing right would 
unnecessarily delay the licence issuance process. Patent holders believe that their right to a 
hearing is inherent and based upon natural justice and several provisions of patent law. This 
question arose in discussion during the first two hearings when deliberations on the merit of 
the application were set aside for a while and parties argued their position on this preliminary 
hiccup. The parties raised several crucial points in their submissions. 
To resolve this matter and decide about the stay petition of Natco, the Delhi Patent Office held 
a hearing on March 19, 2008. This hearing was attended by the parties and representatives of 
the Lawyers Collective, the HIV/AIDS Unit and the MSF Access Campaign. The latter two 
parties attended the proceedings as observers and the counsel of patentees raised objections 
about their presence asserting the proceedings as a private hearing. However, it was finally 
resolved that the observers could attend the proceedings with the objection of patentees placed 
on the record.109  
In favour of their position, patentees relied both on statutory and common law grounds to 
establish the right to hearing before a compulsory licence was issued. The Patentee argued that 
under the notion of ‘natural justice’ and ‘due process’, a hearing opportunity was fundamental 
before any decision adverse to their right was considered. Further reliance was made on Section 
80 of the Patents Act 1970 (India) and Rule 129 of the Patents Rules 2003 (India). A joint reading 
of Section 80 and Rule 129 suggest that the Patent Controller is required to grant a patent 
applicant, or any party to a proceeding, a hearing before exercising any discretionary power 
adversely. Thus, it was argued, the patentees had a right to be heard before the grant of 
compulsory licence.110 Pfizer also relied upon a number of Indian cases to establish its position 
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on the right to be heard and in this regard reliance was made on audi alterum partum.111 The 
same principle was upheld in several other cases such as Union of India v. T.R. Verma112, 
Basudeo Tiway v. Sido Kanhu Uni113 and Udit Narayan Singh v. Additional Member Board of 
Revenue.114  
In response to such assertions, the applicant (Natco) maintained that Section 92A was clear in 
its language and intention and such hearing was deliberately avoided at the time of 
amendments in the law. Section 92A was a clear response to the mandate of the Doha 
Declaration 2001 and the legislature intentionally adopted a fast track and efficient mechanism 
to meet the public health challenges in importing countries. Thus, a clear distinction was made 
between the general compulsory licensing provisions (Sections 84-92) and this provision 
(Section 92A). Domestic compulsory licensing provisions clearly provide a hearing opportunity 
and Section 92A is deliberately silent on this point to expedite the procedure. Natco insisted 
that Section 92A could be construed in the light of the Doha Declaration 2001 which prompted 
the need for rapid response in the case of a public health crisis. Natco maintained that: 
On analysis of the section 92 (A) of the Indian Patents Act, it is clear that law 
specifically excludes any interference or intervention or even participation by the 
patentee. Therefore, the question of contesting the grant of license does not arise. The 
entire mechanism is a departure from the usual procedure of grant of compulsory 
license and is aimed at giving effect to and fulfilling the objectives of said Doha 
Declaration which emphasizes on the rapid response to the urgent needs of the least 
developed countries or developing countries for immediate access to patented 
medicines.115 
Natco also referred to the relevant Canadian legislation (Section 21.14) where no such right was 
incorporated in the law before the issuance of a compulsory licence.116 In response to the 
patentees’ position that certain matters could only be determined with the assistance of 
patentees, Natco relied on the joint publication of WHO/UNDP which could be used to work 
out adequate remuneration in such circumstances without the involvement of the patentees.117 
 
111 Maneka Gandhi v Union of India (1978) 1 SCC 248.  
112 Union of India v T.R. Verma AIR 1957 SC 882.  
113 Basudeo Tiway v Sido Kanhu Uni (1998) 8 SCC 194. 
114 Udit Narayan Singh v Additional Member Board of Revenue AIR 1963 SC 786.  




117 In fact reference was made to: James Love, ‘Remuneration Guidelines for a non voluntary use of a patent on 
medical technologies, UNDP-WHO Health Economic and Drugs TCM Series No. 18 (WHO/TCM/2005.1), 
(2005). 
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It further argued that the common law doctrine of natural justice could not be applied in an 
absolute manner and it had always been regulated under different situations and in view of the 
unambiguous language of Section 92A, general rules could not be attracted.  
The Patent Office finally resolved the matter of the hearing controversy on July 4, 2008. In his 
decision, Hrdev Karar, Assistant Controller of Patents and Design, dismissed the interlocutory 
petition of Natco and allowed the patentees to become parties to proceedings before the Patent 
Office in the matter under Section 92A. The Patent Office decision is important in view of 
future applications of Section 92A and it would eventually pave a way towards elaborative and 
lengthy proceedings before the grant of a compulsory license.  
The decision is mainly about the patentee’s right to participate in proceedings held under 
Section 92A and several other points were also discussed by the Assistant Controller regarding 
the maintainability of Natco’s application. For instance, it is noticed that Natco could not 
substantiate its application for the grant of a compulsory licence by producing a notification 
from the Government of Nepal. The letter which Natco had attached along with its original 
application was declared insufficient in the light of legislative requirement. Natco did not 
submit proof to suggest that there was a public health emergency in Nepal due to the lack of 
availability of the drug. The Assistant Patent Controller, therefore, stated in his order that one 
of the reasons for the ‘hearing’ was to ensure that the provisions of 92 (A) were not ‘abused’. 
The participation of patentees and their hearing right are recognised in the decision in purview 
of Section 92A and the applicant’s submission on this point was turned down. Agreeing with 
the patentees’ arguments on this point, the Assistant Controller of Patents and Design said: 
It may be observed that the requirements as mentioned in section 92A and rules made 
thereunder impliedly demands the presence of the patentee, therefore the doctrine 
“necessary implication or the maxim expression ‘unius est exclusio alterius’ need not to be 
applied. The principle audi alteration partem would be more beneficial for proper 
administration of justice. Therefore, the patentee is required to be invited to the hearing 
in respect of proceedings of section 92(A).118 
The hearing controversy is now resolved by this decision and the remaining matter is to be 
decided on its merits. This initial controversy raised important procedural questions which 
have the potential to stall a compulsory licence application for a considerable time. An 
unrestricted and full-fledged hearing right may hamper the development of a standard working 
procedure which can be later employed by other generic companies to apply for compulsory 
licences under Section 92A. This first case is highly important not only for Indian 
manufacturers but also for the rest of the developing world as the placement of a quick and 
efficient mechanism in India would help them activate their domestic regulations to important 
 
118 Ibid. 13.  
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cheaper drugs from generic resources. Obviously any unnecessary delay or cumbersome 
procedure should be considered against the legislative intent and procedural requirements 
under Section 92A. 
J. Withdrawal of Application by Natco 
After this decision, it was expected that the matter would shift to normal proceedings and the 
patent office would decide about the grant of compulsory licence after hearing both parties. 
Though the decision was disappointing for Natco it was expected that Natco would strongly 
push its case on the merits for the grant of a compulsory licence. However, in September 2008, 
Natco requested the Controller of Patents to withdraw its applications for compulsory licenses 
for export of the generic anti-cancer drugs sunitinib and erlotinib.119 
Apparently it was an unexpected move although some commentators noted that it was 
anticipated after Patent Office’s decisions on Natco’s interlocutory petition. Shamnad Basheer 
observed that: 
[P]atent office was concerned that the Doha CL process ought not to be abused by 
generic manufacturers that wished to make a quick buck. Therefore, the best way to 
ensure this was to hear the other side as well … Natco’s decision to withdraw its 
application may have stemmed from a fear that it would lose on merits.120 
The outcome is indeed disappointing for a variety of reasons. First, this case was a good chance 
for Indian generic companies to test the application of export oriented compulsory licences. 
Second, the decision of the Patent Office was unreasonable in that it had indeed determined 
the outcome of Natco’s application beforehand. The decision expressed serious doubts about 
the maintainability of a compulsory licensing application at a stage when there was controversy 
about the hearing matter. Natco had also apparently rushed into this matter without 
completing its homework in Nepal, and it could not substantiate its case for the grant of 
compulsory licence on public health grounds.  
 
119 C.H. Unnikrishnan, ‘Natco withdraws plea on making patented cancer drugs’, Mint: The Wall Street Journal, Sep 
28 2008 at http://www.livemint.com/2008/09/28214903/Natco-withdraws-plea-on-making.html 
120 Shamnad Basheer, ‘Breaking News: Natco Withdraws “Doha” Compulsory Licence Application’ on SpicyIP 
(September 28, 2008) at http://spicyipindia.blogspot.com/2008/09/breaking-news-natco-withdraws-doha.html 




In conclusion, one possible way of maintaining Indian exports at their current level is through 
the strategic use of compulsory licensing provisions which are incorporated in Indian law. I 
have analysed this potential in the light of early compulsory licensing instances. Natco’s 
application for a compulsory licence highlights the ambiguities in the law and procedure. 
Contrary to the general assumptions, the system did not work efficiently in this first case for a 
variety of reasons which could be attributed to the Patent Office, patent law, the applicant and 
patent holders. However, the main reasons were procedural ambiguities and the lack of 
appropriate homework by the applicant 
I have argued that both the international framework (WTO Waiver Decision 2003) and the 
domestic rules (Indian compulsory licensing provisions) will not help in achieving the objectives 
of the Doha Declaration 2001. Four main reasons are cited here to support this position. First, 
the complexity of rules is a vital constraint and it operates both on the levels of treaty law and 
domestic regulation. Second, pharmaceutical firms view the export potential in terms of market 
size and the profits involved in such supply. Because of the complexity of rules, and fragmented 
markets, the firms may be less inclined to engage in export oriented production if their 
commercial expectations are largely unmet. Third, the chances of supplies being available 
becomes more unlikely especially if the firms have to make specific technological investments to 
produce the drugs required for a limited time in a restricted territory. Such technological 
investment is essential to the manufacture of new drugs which are constantly in demand in 
most of the African countries. Fourth, the Indian government lacks the political will or 
enthusiasm to engage in the wide scale use of Section 92A.121 The Indian government has a 
vested interest in integrating into the global economy and trading network.  
 
121 Sanjeev Choudhary and Khomba Singh, ‘Government may use Compulsory Licensing for Drug Companies 
only in Emergency’, The Economic Times, 3 April 2008, at http://economictimes.indiatimes.com/
News/News_By_Industry/Healthcare__Biotech/Healthcare/Govt_may_use_compulsory_licensing_for_drug_com
panies_only_in_emergency/articleshow/2921237.cms 


















Figure 4.1 Four Modes of Compulsory Licensing under the Patents Act 1970 (India) as amended at 2005 
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